Cabozantinib,Nivolumab,Ipilimumab
BMS
['nivolumab', 'renal,(-adrenal)', 'nivo', 'cabozantinib']
 very intriguing data presented by #asco23 phase ii study of nivolumab and cabozantinib for variant histology renal cell cancer. 76% disease control rate and 18% objective response rate. 
🎗Oncologist|🧬Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter